Literature DB >> 25259568

Co-prevalence of other tumors in patients harboring pituitary tumors.

William T Couldwell1, Lisa A Cannon-Albright.   

Abstract

OBJECT: The cause of most pituitary tumors remains unknown, although a genetic contribution is recognized for some. The prevalence of pituitary tumors in the general population is high. Analyzing the Utah Population Database (UPDB), the authors investigated the co-prevalence of other independent primary tumors in patients with known pituitary tumors, both benign and malignant, and in the relatives of these patients.
METHODS: The authors identified individuals in the Utah Cancer Registry diagnosed with pituitary tumors who also had genealogy data in the UPDB and then calculated relative risks (RRs) of other tumors in these patients and their relatives.
RESULTS: Among the 591 individuals with pituitary tumors, 16 (2.7%) had a malignant pituitary tumor and 77 (13%) had independent primary tumors of other origin. Overall, this is significantly higher than expected (70.6 expected, p = 0.009) within the general population (RR = 1.32, 95% CI 1.06-1.61). A significant excess for several different cancer sites was observed among the first-, second-, and third-degree relatives of the cases, including prostate and other cancers. Independent primary tumors at other sites have markedly elevated co-prevalence in patients harboring pituitary tumors and among their close and distant relatives.
CONCLUSIONS: This information will prove useful for counseling patients in whom pituitary tumors have been diagnosed and suggests strong genetic or environmental co-risks for the development of other tumors.

Entities:  

Keywords:  RR = relative risk; SEER = Surveillance, Epidemiology, and End Results; UCR = Utah Cancer Registry; UPDB = Utah Population Database; Utah Population Database; co-prevalence; genetics; pituitary neoplasm; pituitary surgery; relative risk

Mesh:

Year:  2014        PMID: 25259568     DOI: 10.3171/2014.8.JNS132139

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas.

Authors:  Naama Peltz-Sinvani; Ruth Percik; Inbal Uri; Sapir Kon Kfir; Amir Tirosh; Amit Tirosh
Journal:  Endocrine       Date:  2021-05-12       Impact factor: 3.633

2.  Vestibular schwannoma and pituitary adenoma in the same patient: coincidence or novel clinical association?

Authors:  Matthew L Carlson; Neil S Patel; Amy E Glasgow; Elizabeth B Habermann; Brandon R Grossardt; Michael J Link
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

3.  Familial Cancer Clustering in Patients with Prolactinoma.

Authors:  Sandra Pekic; Ivan Soldatovic; Dragana Miljic; Marko Stojanovic; Mirjana Doknic; Milan Petakov; Vera Popovic
Journal:  Horm Cancer       Date:  2018-09-08       Impact factor: 3.869

4.  Commentary.

Authors:  Lorenzo Curtò
Journal:  J Neurosci Rural Pract       Date:  2015 Jul-Sep

5.  A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.

Authors:  Tajana Tešan Tomić; Josefin Olausson; Annica Wilzén; Magnus Sabel; Katarina Truvé; Helene Sjögren; Sándor Dósa; Magnus Tisell; Birgitta Lannering; Fredrik Enlund; Tommy Martinsson; Pierre Åman; Frida Abel
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

6.  Commentary on "Co-Occurrence of Pituitary Adenoma With Suprasellar and Olfactory Groove Meningiomas".

Authors:  Lorenzo Curtò; Salvatore Cannavò
Journal:  Basic Clin Neurosci       Date:  2017 Nov-Dec

7.  Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia.

Authors:  Meng Hao; Miguel Angel Luque-Fernandez; Diana Lopez; Kathryn Cote; Jessica Newfield; Molly Connors; Anand Vaidya
Journal:  Int J Endocrinol       Date:  2019-11-03       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.